Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANACOMP trial of anakinra versus IVIG retreatment in IVIG-resistant Kawasaki disease
2020-003194-22Phase 3Active
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Sep 2020
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial in Kawasaki disease (KD) comparing Anakinra with IVIG retreatment (2 arms). Primary endpoint: Primary efficacy endpoint. Started Sep 2020; status: active.
02
Drugs
anakinrapolyvalent human immunoglobulin
03
Conditions
Kawasaki disease (KD)
Beyond the preview
Go deeper on 2020-003194-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-003194-22.